[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caris Life Sciences Inc (CAI)

Caris Life Sciences Inc (CAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,407,113
  • Shares Outstanding, K 282,651
  • Annual Sales, $ 812,030 K
  • Annual Income, $ -68,090 K
  • EBIT $ -46 M
  • EBITDA $ 80 M
  • 60-Month Beta N/A
  • Price/Sales 6.60
  • Price/Cash Flow 11.89
  • Price/Book 9.26

Options Overview Details

View History
  • Implied Volatility 93.83% (+6.45%)
  • Historical Volatility 62.81%
  • IV Percentile 81%
  • IV Rank 51.03%
  • IV High 132.24% on 03/18/26
  • IV Low 53.81% on 01/21/26
  • Expected Move (DTE 8) 1.15 (5.78%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 484
  • Volume Avg (30-Day) 135
  • Put/Call OI Ratio 1.34
  • Today's Open Interest 6,434
  • Open Int (30-Day) 6,585
  • Expected Range 18.69 to 20.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.02
  • Number of Estimates 4
  • High Estimate $0.03
  • Low Estimate $-0.06
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.40 +14.06%
on 04/29/26
22.16 -10.47%
on 04/21/26
+1.09 (+5.81%)
since 04/07/26
3-Month
16.28 +21.87%
on 03/30/26
23.00 -13.74%
on 02/10/26
-2.16 (-9.82%)
since 02/06/26

Most Recent Stories

More News
Caris Life Sciences Reports First Quarter 2026 Financial Results

Revenue growth of 79% driven by strong performance in molecular profiling services

CAI : 19.84 (+3.71%)
Caris Life Sciences Reports Tomorrow but Reimbursement Reality May Finally Catch Up

Barchart Research What to Expect from CAI Earnings CAI Generated May 6, 2026 Current Price $19.13 EPS Estimate $$-0.02 Consensus Rating Strong Buy Average Move 8.68% Caris Life Sciences Reports Tomorrow...

CAI : 19.84 (+3.71%)
Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Caris MI Clarity leverages AI to transform how recurrence risk is understood and applied in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer

CAI : 19.84 (+3.71%)
Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies

IRVING, Texas , May 4, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient‑centric, next‑generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 19.84 (+3.71%)
Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients

Caris AI Insights are proprietary and only available to Caris Life Sciences customers

CAI : 19.84 (+3.71%)
Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference

IRVING, Texas , April 24, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 19.84 (+3.71%)
Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

IRVING, Texas , April 20, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 19.84 (+3.71%)
Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center

IRVING, Texas , April 17, 2026 /PRNewswire/ --  Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today...

CAI : 19.84 (+3.71%)
Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients

Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patients with a complete pathway from diagnosis to treatment across more than 600 locations nationwide

CAI : 19.84 (+3.71%)
Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients

Caris AI Insights are proprietary and only available to Caris Life Sciences customers  

CAI : 19.84 (+3.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Caris Life Sciences Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring and precision medicine enabling aspects. Caris Life Sciences Inc. is based in Irving,...

See More

Key Turning Points

3rd Resistance Point 21.29
2nd Resistance Point 20.66
1st Resistance Point 20.25
Last Price 19.84
1st Support Level 19.21
2nd Support Level 18.58
3rd Support Level 18.17

See More

52-Week High 42.50
Fibonacci 61.8% 32.48
Fibonacci 50% 29.39
Fibonacci 38.2% 26.30
Last Price 19.84
52-Week Low 16.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.